About us Contacts Drug interactions: 390 212
Drug search by name

Rucaparib and Zykadia

Determining the interaction of Rucaparib and Zykadia and the possibility of their joint administration.

Check result:
Rucaparib <> Zykadia
Relevance: 23.06.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Consumer information for this interaction is not currently available.MONITOR: Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations and the risk of adverse effects of rucaparib, which has been shown in vitro to be a substrate of the isoenzyme. However, the effects on the pharmacokinetics of rucaparib have not been evaluated in vivo. MANAGEMENT: Caution is advised if rucaparib is used concomitantly with potent CYP450 3A4 inhibitors. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy with rucaparib. References EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):

Professional:

MONITOR: Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations and the risk of adverse effects of rucaparib, which has been shown in vitro to be a substrate of the isoenzyme. However, the effects on the pharmacokinetics of rucaparib have not been evaluated in vivo.

MANAGEMENT: Caution is advised if rucaparib is used concomitantly with potent CYP450 3A4 inhibitors. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy with rucaparib.

References
  • EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):
Rucaparib

Generic Name: rucaparib

Brand name: Rubraca

Synonyms: n.a.

Zykadia

Generic Name: ceritinib

Brand name: Zykadia

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction